Thalidomide-based multidisciplinary treatment for patients with advanced hepatocellular carcinoma: A retrospective analysis

Table 1 The clinical characteristics of 53 patients with hepatocellular carcinoma

Characteristic	n (%)
Age, yr (median)	61 (range, 29-88)
Sex
Male	44 (83.0)
Female	9 (17.0)
Type of hepatitis
Hepatitis B	30 (56.6)
Hepatitis C	20 (37.7)
Hepatitis B + C	1 (1.9)
Child-Pugh classification
A	30 (56.6)
B	12 (22.6)
C	1 (1.8)
TNM stage
I	0 (0)
II	6 (11.2)
IIIA	11 (20.8)
IIIB	3 (5.7)
IIIC	6 (11.2)
IV	24 (45.3)
Okuda stage
I	27 (51.9)
II	16 (30.8)
III	1 (1.9)
BCLC stage
A	2 (3.9)
B	7 (13.5)
C	37 (71.2)
D	1 (1.9)
Extrahepatic metastasis
Yes	25 (47.2)
No	28 (52.8)
Portal vein thrombosis
Yes	26 (49.1)
No	26 (49.1)
Unknown	1 (1.8%)
Site of extrahepatic metastasis
Lung	11 (21.2)
Bone	6 (11.5)
Brain	1 (1.9)
Others	7 (13.5)
Prior therapy
Surgery	12 (22.6)
TACE	16 (30.2)
TAE	13 (24.5)
Radiation therapy	10 (18.9)
RFA	10 (18.9)
No therapy	10 (18.9)
Duration of treatment, mo
Median	6.0 (range, 1.5-53.9)
AFP level
> 400 ng/mL	31 (58.5)
< 400 ng/mL	22 (41.5)

BCLC: Barcelona Clinic Liver Cancer; TACE: Transarterial chemoembolization; TAE: Transarterial embolization; RFA: Radiofrequency ablation; AFP: Alpha fetoprotein; TNM: Tumor node metastasis.